Drugmaker pays 23andMe $20 million for access to user DNA information
GSK Plc and 23andMe are expanding their partnership to give the drugmaking company access to the genetic company's database.
"With approximately 50 programs developed over the last five years, we are thrilled to work with GSK in discovering genetically validated targets," said Anne Wojcicki, 23andMe CEO and co-founder. "The continued relationship with GSK demonstrates the power of the 23andMe research platform to consistently produce novel insights for therapeutic development, rooted in human genetics."
https://www.ksby.com/drugmaker-pays-23andme-20-million-for-access-to-user-dna-information